Multivariate linear regression of clinical measures with RBC MTX PG levels and pharmacogenetic measurements in the 226 patients
| Dependent variables | ||||
|---|---|---|---|---|
| Tender joints (n) | Swollen joints (n) | Physician’s global assessment of disease activity (10 cm VAS) | mHAQ | |
| The independent variables were RBC MTX PGs (in nmol/l) and the pharmacogenetic index. Covariates included in the analysis were the presence of rheumatoid factors, the duration of the disease, the concomitant administration of low dose corticosteroids, and the MTX dose administered. Estimates (SE) with the p value are given for MTX dose, RBC MTX PGs, and the pharmacogenetic index. Global R and R2 are also given. | ||||
| Global R (R2) | 0.33 (0.11) | 0.28 (0.08) | 0.35 (0.12) | (0.09) |
| MTX dose (mg/week) | 0.263 (0.076) (p<0.001) | 0.151 (0.068) (p = 0.027) | 0.113 (0.031) (p<0.001) | 0.024 (0.002) (p = 0.002) |
| RBC MTX PGs (nmol/l) | −0.050 (0.015) (p = 0.001) | −0.022 (0.013) (p = 0.011) | −0.0257 (0.006) (p<0.001) | −0.004 (0.001) (p = 0.006) |
| Pharmacogenetic index | −0.981 (0.336) (p = 0.003) | −0.877 (0.300) (p = 0.003) | −0.260 (0.136) (p = 0.049) | −0.063 (0.034) (p = 0.084) |